IL236007B - Macrocyclic inhibitors of flavoviride viruses - Google Patents
Macrocyclic inhibitors of flavoviride virusesInfo
- Publication number
- IL236007B IL236007B IL236007A IL23600714A IL236007B IL 236007 B IL236007 B IL 236007B IL 236007 A IL236007 A IL 236007A IL 23600714 A IL23600714 A IL 23600714A IL 236007 B IL236007 B IL 236007B
- Authority
- IL
- Israel
- Prior art keywords
- flaviviridae viruses
- macrocyclic inhibitors
- macrocyclic
- inhibitors
- flaviviridae
- Prior art date
Links
- 241000710781 Flaviviridae Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657562P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044812 WO2013185093A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL236007A0 IL236007A0 (en) | 2015-02-01 |
| IL236007B true IL236007B (en) | 2018-01-31 |
Family
ID=48626704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236007A IL236007B (en) | 2012-06-08 | 2014-11-30 | Macrocyclic inhibitors of flavoviride viruses |
Country Status (33)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| IN2014MN02652A (enExample) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc | |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SI2859009T1 (sl) * | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| US20150150897A1 (en) | 2013-12-02 | 2015-06-04 | Gilead Pharmasset Llc | Methods of treating hepatitis c virus infection in subjects with cirrhosis |
| TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
| ES2669208T3 (es) | 2014-01-06 | 2018-05-24 | Bristol-Myers Squibb Company | Derivados de pirrolidinilsulfona y su uso como moduladores de ROR gamma |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| SG11201606876RA (en) | 2015-03-04 | 2016-10-28 | Gilead Sciences Inc | Toll like receptor modulator compounds |
| MA42684A (fr) | 2015-08-26 | 2018-07-04 | Gilead Sciences Inc | Modulateurs deutérés du récepteur toll |
| CA3000822A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20170127A1 (ar) | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018136559A1 (en) * | 2017-01-17 | 2018-07-26 | The Regents Of The University Of California | Methods for treating flaviviruses and zika infections |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| CA3056970A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2018232174A2 (en) * | 2017-06-16 | 2018-12-20 | Avalon Flaviviral Therapeutics (Hk) Limited | Compositions and methods for treating flavivirus infections |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102891807B1 (ko) | 2017-08-22 | 2025-12-01 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781565A1 (en) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN112384505B (zh) | 2018-07-06 | 2025-05-27 | 吉利德科学公司 | 治疗性的杂环化合物 |
| AU2019297428C1 (en) | 2018-07-06 | 2023-03-23 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
| CN113412249A (zh) * | 2019-02-08 | 2021-09-17 | 大金工业株式会社 | 有机化合物的制造方法 |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| MX2022005359A (es) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121471132A (zh) * | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| EP4144353A4 (en) * | 2020-04-30 | 2024-08-28 | FUJIFILM Toyama Chemical Co., Ltd. | THERAPEUTIC AGENT AGAINST CORONAVIRUS INFECTION FORMED BY COMBINATION OF A PYRAZINE DERIVATIVE AND ANOTHER THERAPEUTIC DRUG AGAINST CORONAVIRUS INFECTION |
| LT4192474T (lt) | 2020-08-07 | 2025-11-25 | Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas | |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| GB202207348D0 (en) | 2022-05-19 | 2022-07-06 | Cypralis Ltd | Macrocyclic compounds and uses thereof |
| CN115677482A (zh) * | 2022-11-22 | 2023-02-03 | 上海吉奉生物科技有限公司 | 一种手性α-羟基酸的合成方法 |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62193147A (ja) | 1986-02-19 | 1987-08-25 | Toshiba Corp | 半導体装置の製造方法 |
| AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| EP1229910A4 (en) | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| ATE461926T1 (de) | 2004-06-30 | 2010-04-15 | Schering Corp | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer |
| CA2612344A1 (en) | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| RU2427372C2 (ru) * | 2005-06-17 | 2011-08-27 | Новартис Аг | Применение санглиферина для лечения вируса гепатита с |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US20100285056A1 (en) | 2008-01-09 | 2010-11-11 | Konkuk University Industrial Cooperation Corp. | Baculovirus-Based Vaccines |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| DK2382198T3 (da) * | 2008-12-23 | 2013-09-30 | Janssen Pharmaceuticals Inc | Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease |
| TWI491609B (zh) | 2010-01-15 | 2015-07-11 | Gilead Sciences Inc | 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類 |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| WO2012040040A1 (en) | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| AR084217A1 (es) | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| AU2013273118B2 (en) | 2012-06-08 | 2015-11-05 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts |
| SI2859009T1 (sl) | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
| IN2014MN02652A (enExample) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc |
-
2013
- 2013-06-05 AR ARP130101987 patent/AR091279A1/es unknown
- 2013-06-06 UY UY0001034851A patent/UY34851A/es not_active Application Discontinuation
- 2013-06-06 TW TW102120164A patent/TWI616448B/zh active
- 2013-06-07 PT PT137292405T patent/PT2861601T/pt unknown
- 2013-06-07 KR KR1020157000179A patent/KR102185152B1/ko active Active
- 2013-06-07 AU AU2013270670A patent/AU2013270670B2/en active Active
- 2013-06-07 US US13/913,288 patent/US9062092B2/en active Active
- 2013-06-07 AP AP2015008189A patent/AP2015008189A0/xx unknown
- 2013-06-07 BR BR112014030639A patent/BR112014030639A2/pt not_active Application Discontinuation
- 2013-06-07 PL PL13729240T patent/PL2861601T3/pl unknown
- 2013-06-07 CA CA2875690A patent/CA2875690C/en active Active
- 2013-06-07 JP JP2015516258A patent/JP6273268B2/ja active Active
- 2013-06-07 EP EP13729240.5A patent/EP2861601B1/en active Active
- 2013-06-07 EP EP18155377.7A patent/EP3392253B1/en active Active
- 2013-06-07 ES ES18155377T patent/ES2894269T3/es active Active
- 2013-06-07 ES ES13729240.5T patent/ES2672480T3/es active Active
- 2013-06-07 IN IN2657MUN2014 patent/IN2014MN02657A/en unknown
- 2013-06-07 NZ NZ703062A patent/NZ703062A/en not_active IP Right Cessation
- 2013-06-07 MX MX2014014765A patent/MX358372B/es active IP Right Grant
- 2013-06-07 SI SI201331014T patent/SI2861601T1/en unknown
- 2013-06-07 EA EA201492188A patent/EA027134B1/ru not_active IP Right Cessation
- 2013-06-07 PE PE2014002395A patent/PE20150862A1/es not_active Application Discontinuation
- 2013-06-07 SG SG10201703969PA patent/SG10201703969PA/en unknown
- 2013-06-07 MD MDA20140135A patent/MD20140135A2/ro not_active Application Discontinuation
- 2013-06-07 MA MA37712A patent/MA37712B1/fr unknown
- 2013-06-07 WO PCT/US2013/044812 patent/WO2013185093A1/en not_active Ceased
- 2013-06-07 SG SG11201408064PA patent/SG11201408064PA/en unknown
- 2013-06-07 CN CN201380040628.8A patent/CN104781261B/zh active Active
- 2013-07-06 UA UAA201413748A patent/UA115664C2/uk unknown
- 2013-08-16 NO NO13830006A patent/NO2885641T3/no unknown
-
2014
- 2014-11-30 IL IL236007A patent/IL236007B/en active IP Right Grant
- 2014-12-05 PH PH12014502739A patent/PH12014502739B1/en unknown
- 2014-12-05 CL CL2014003337A patent/CL2014003337A1/es unknown
- 2014-12-15 ZA ZA2014/09215A patent/ZA201409215B/en unknown
-
2015
- 2015-01-07 EC ECIEPI2015435A patent/ECSP15000435A/es unknown
- 2015-01-19 CR CR20150018A patent/CR20150018A/es unknown
- 2015-05-21 US US14/719,242 patent/US9642889B2/en active Active
-
2016
- 2016-04-08 US US15/094,777 patent/US20160220633A1/en not_active Abandoned
-
2017
- 2017-02-02 US US15/423,469 patent/US10472392B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201409215B (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| IL236005A0 (en) | Macrocyclic inhibitors of flavoviride viruses | |
| IL236006A0 (en) | Macrocyclic inhibitors of flavoviride viruses | |
| IL269662A (en) | Hepatitis C virus inhibitors | |
| SI2649076T1 (sl) | Makroklinični inhibitorji flavivirusov | |
| AP3576A (en) | Inhibitors of flaviviridae viruses | |
| AP2012006413A0 (en) | Inhibitors of flaviviridae viruses | |
| AP4029A (en) | Inhibitors of beta-secretase | |
| SG11201403891SA (en) | Purification of flaviviruses | |
| IL242314A (en) | Iap inhibitors | |
| AP2015008261A0 (en) | Inhibitors of beta-secretase | |
| PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |